# Genesis Consortium

> Genesis Consortium is a VC fund backing Biotechnology, Fashion and Biopharma. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 7
- Last investment: Sep 2023
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/showcase/genesisconsortium/
- X (Twitter): https://twitter.com/GenConsortium
- Website: https://genesisconsortium.org/

Genesis Consortium is an alliance of venture funds and corporations to promote human and planetary health.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $525k–$3.6M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 57% |
| Fashion | 1 | 14% |
| Biopharma | 1 | 14% |
| Health Care | 1 | 14% |
| Architecture | 1 | 14% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 6 | 86% |
| Pre-Seed | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 71% |
| Turkey | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Calder Biosciences | Developing increasingly challenging vaccine targets requires increasingly sophisticated technologies. Over the last century, vaccines have made essential contributions to the doubling of human life expectancy. Calder engineers next-generation vaccines that will further protect against the most intractable and life-threatening viruses. Viruses haveevolved to become shapeshifters that can evade and distract our immune system by hiding some of their most vulnerable sites. History has shown that pandemics are not only lethal but also inevitable. Currently, the vaccines we know best poorly protect against pandemics and other viral outbreaks and leave many at-risk populations unprotected. By combining structure-based design as part of a novel manufacturing process, Calder’s unique 3D-Vaxlock technology generates molecular staples that lock vaccines into their most potent shape. Their initial focus is on generating a universal flu vaccine that protects against all seasonal strains and an RSV vaccine specifically for the elderly. With this platform, they have the ability to create treatments that better protect against life-threatening diseases with exceptional safety, efficacy, and durability. Calder’s next generation vaccines will prevent severe disease and deaths, alleviate a substantial burden on the healthcare system, and allow billions of people to lead healthy lives. | $625K | Seed | Sep 12, 2023 |  |
| Wayfinder Biosciences | Wayfinder Biosciences is a biotechnology company developing orally available small molecule drugs that modulate the function of the RNAs encoding key disease targets. The company's proprietary platform combines unique screening and computational technologies to rapidly discover potent, selective and biologically active RNA-targeting smallmolecules. Wayfinder's programs are focused on traditionally inaccessible targets in oncology and neurodegenerative disease. Wayfinder Biosciences was established in 2021 and is headquartered in Seattle, WA. | $3.6M | Seed | Oct 17, 2022 |  |
| Gozen Bioworks | Gozen Bioworks is a bio-tech company that invents and develops next-gen microbe-derived biomaterials. | $525K | Seed | Sep 21, 2022 |  |
| MAA'VA | MAA’VA™ is developing a proprietary sustainable carbon negative construction material, turning plastic and nonplastic waste into eco-material, advancing solutions to climate change crisis, waste crisis, global river sand shortage, water scarcity and rapid urbanization. Our eco-concrete can be used for both conventional and 3D printingconstruction. By optimizing 3D printing technology we can build environmentally friendly low cost housing with eco-concrete in one day for 1/10th of the construction cost and half of the construction waste. | $525K | Seed | Sep 21, 2022 |  |
| West~bourne | west~bourne is creating the next-generation go-to brand for plant powered and planet positive provisions. | $525K | Seed | Sep 21, 2022 |  |
| Mirá Biotech | Mirá is launching a biofuel breakthrough to subvert coal dependency in heavy industries. | $525K | Seed | Sep 21, 2022 |  |
| MAA'VA | MAA’VA™ is developing a proprietary sustainable carbon negative construction material, turning plastic and nonplastic waste into eco-material, advancing solutions to climate change crisis, waste crisis, global river sand shortage, water scarcity and rapid urbanization. Our eco-concrete can be used for both conventional and 3D printingconstruction. By optimizing 3D printing technology we can build environmentally friendly low cost housing with eco-concrete in one day for 1/10th of the construction cost and half of the construction waste. | $525K | Pre-Seed | Sep 21, 2022 |  |

7 of 7 investments shown.

## Co-investors
- [SOSV SF & NY (Fka IndieBio)](https://shizune.co/investors/profile/synbio-axlr8r) — VC Fund, 7 deals together
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund, 6 deals together
- [BoxOne Ventures](https://shizune.co/investors/profile/boxone-ventures) — VC Fund, 1 deal together
- [Conscience VC](https://shizune.co/investors/profile/conscience-vc) — VC Fund, 1 deal together
- [Divergent Capital](https://shizune.co/investors/profile/divergent-capital-1c5e) — VC Fund, 1 deal together
- [SOSV HAX](https://shizune.co/investors/profile/hax-accelerator) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Alesta Yatırım](https://shizune.co/investors/profile/alesta-girisim) — VC Fund
- [APY Ventures](https://shizune.co/investors/profile/apy-ventures) — VC Fund
- [Boğaziçi Ventures](https://shizune.co/investors/profile/bo%C4%9Fazi%C3%A7i-ventures) — VC Fund

## Featured in investor lists
- [Manufacturing VC Funds in Turkey](https://shizune.co/investors/manufacturing-vc-funds-turkey)
- [Biotechnology Investors in Brazil](https://shizune.co/investors/biotechnology-investors-brazil)
- [Biotechnology VC Funds in Brazil](https://shizune.co/investors/biotechnology-vc-funds-brazil)
- [Biotech Investors in Brazil](https://shizune.co/investors/biotech-investors-brazil)
- [Biotech VC Funds in Turkey](https://shizune.co/investors/biotech-vc-funds-turkey)
- [Climate Investors in Turkey](https://shizune.co/investors/climate-investors-turkey)

## FAQ

### What does Genesis Consortium invest in?

Genesis Consortium invests primarily in Biotechnology, Fashion and Biopharma startups, most often at Seed and Pre-Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Genesis Consortium's check size?

Genesis Consortium typically joins rounds of $525k–$3.6M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Genesis Consortium participates in.

### When did Genesis Consortium last invest?

The most recent investment recorded for Genesis Consortium closed in Sep 2023. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co